EntroGen Inc. announced that its CRCdx RAS Mutation Detection Kit has received national coverage from the US Centers for Medicare & Medicaid Services (CMS).
This milestone significantly enhances access to precision oncology for Medicare beneficiaries diagnosed with colorectal cancer, enabling broader adoption of CRCdx nationwide.
The CRCdx RAS Mutation Detection Kit is the first FDA-approved real-time PCR based companion diagnostic for identifying patients eligible for treatment with Vectibix (panitumumab), based on the absence of KRAS and NRAS mutations. Now with CMS coverage, laboratories and healthcare providers can confidently integrate CRCdx into clinical workflows without the barrier of out-of-pocket patient costs.
CRCdx is available for immediate use in clinical laboratories across the United States.
